

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 May 2001 (10.05.2001)

PCT

(10) International Publication Number
WO 01/32177 A1

- (51) International Patent Classification⁷: **A61K 31/439**, C07D 221/22, 401/06 (74) Common Representative: **MERCK & CO., INC.**; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- (21) International Application Number: **PCT/US00/29577** (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 26 October 2000 (26.10.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/162,261 29 October 1999 (29.10.1999) US
- (71) Applicant (*for all designated States except US*): **MERCK & CO., INC.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **THOMPSON, Wayne** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **CLAREMON, David, A.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **MUNSON, Peter, M.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- *With international search report.*
- *Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **2-AZA-BICYCLO[2.2.2]OCTANE NMDA/NR2B ANTAGONISTS**

(57) Abstract: Novel 2-aza-bicyclo[2.2.2]octanes substituted in the 2-position are effective as NMDA NR2B antagonists useful for relieving pain.

WO 01/32177 A1

TITLE OF THE INVENTION

5 2-AZA-BICYCLO[2.2.2]OCTANE NMDA/NR2B ANTAGONISTS

BACKGROUND OF THE INVENTION

Field of the Invention

10 This invention relates to novel 2-aza-bicyclo[2.2.2]octanes. In particular, this invention relates to novel 2-aza-bicyclo[2.2.2]octanes substituted in the 2-position that are effective as NMDA NR2B antagonists useful for relieving pain.

 Ions such as glutamate play a key role in processes related to chronic pain and pain-associated neurotoxicity – primarily by acting through N-methyl-D-
15 aspartate (“NMDA”) receptors. Thus, inhibition of such action – by employing ion channel antagonists, particularly NMDA antagonists – can be beneficial in the treatment and control of pain.

 Known NMDA antagonists include ketamine, dextromethan, and 3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (“CPP”). Although these
20 compounds have been reported (J.D. Kristensen, et al., *Pain*, 51:249-253 (1992); K. Eide, et al., *Pain*, 61:221-228 (1995); D.J. Knox, et al., *Anaesth. Intensive Care* 23:620-622 (1995); and M.B. Max, et al., *Clin. Neuropharmacol.* 18:360-368 (1995)) to produce symptomatic relief in a number of neuropathies including postherpetic neuralgia, central pain from spinal cord injury, and phantom limb pain, widespread
25 use of these compounds is precluded by their undesirable side effects. Such side effects at analgesic doses include psychotomimetic effects such as dizziness, headache, hallucinations, dysphoria, and disturbances of cognitive and motor function. Additionally, more severe hallucinations, sedation, and ataxia are produced at doses only marginally higher than analgesic doses. Thus, it would be desirable to
30 provide novel NMDA antagonists that are absent of undesirable side effects or that produces fewer and/or milder side effects.

 NMDA receptors are heteromeric assemblies of subunits, of which two major subunit families designated NR1 and NR2 have been cloned. Without being bound by theory, it is generally believed that the various functional NMDA receptors
35 in the mammalian central nervous system (“CNS”) are only formed by combinations


- of NR1 and NR2 subunits, which respectively express glycine and glutamate recognition sites. The NR2 subunit family is in turn divided into four individual subunit types: NR2A, NR2B, NR2C, and NR2D. I. Ishii, et al., *J. Biol. Chem.*, 268:2836-2843 (1993), A. Wenel, et al., *NeuralReport*, 7:45-48 (1995), and D.J. Laurie et al., *Mol. Brain Res.*, 51:23-32 (1997) describe how the various resulting combinations produce a variety of NMDA receptors differing in physiological and pharmacological properties such as ion gating properties, magnesium sensitivity, pharmacological profile, as well as in anatomical distribution.
- For example, while NR1 is found throughout the brain, NR2 subunits are differentially distributed. In particular, it is believed that the distribution map for NR2B lowers the probability of side effects while producing pain relief. For example, S. Boyce, et al., *Neuropharmacology*, 38:611-623(1999) describes the effect of selective NMDA NR2B antagonists on pain with reduced side-effects. Thus, it would be desirable to provide novel NMDA antagonists that target the NR2B receptor.
- International Patent Publication WO94/21615 describes benzimidazole-piperidine compounds utilized as dopamine D4 antagonists. Phenol compounds described as NMDA antagonists are described in U.S. patent Nos. 5,306,723 and 5,436,255, and in International Patent Publications WO91/17156, WO92/19502, WO93/02052, WO94/29571, WO95/28057, WO96/37226, and EP 04422506. Benzyl piperidines substituted with phenols or imidazoles are described in Z.-L. Zhou, et al., *J. Medicinal Chemistry*, 42:2993-3000(1999); T.F. Gregory, et al., Poster #94, 218th National Meeting American Chemical Society, New Orleans, Louisiana, August 22-26, 1999. Other NMDA NR2B selective compounds are described in European Patent Publication EP 787493 and *British J. Pharmacol.*, 123:463(1998). However, there continues to be a need for novel NMDA antagonists that target the NR2B receptor.

SUMMARY OF THE INVENTION

- The present invention relates to 2-aza-bicyclo[2.2.2]octanes substituted in the 2-position with benzimidazoles, imidazopyridines, phenols or imidazoles either directly or through a C₁-C₄alkyl, cycloalkyl, hydroxyalkyl, alkoxy or aminoalkyl chain. The present invention also forms novel pharmaceutical compositions utilizing these novel compounds. Further, this invention includes novel methods to treat pain by utilizing the novel compounds.

DETAILED DESCRIPTION OF THE INVENTION

In one aspect, the compounds of this invention are represented by Formula (I):



(I)

or pharmaceutically acceptable salts thereof, wherein

R₁ is 2-benzimidazole, 4-imidazole, 2-imidazopyridine, 2-indole, 2-quinazoline, or 4-phenol;

R₂ is phenyl, optionally substituted with one to five substituents, each substituent independently being chloro, fluoro, bromo, C₁-C₄alkyl, trifluoromethyl, hydroxy, or carboxy;

L₁ is C₁-C₄alkyl, C₁-C₄alkenyl, C₁-C₄alkynyl, C₁-C₄alkoxy, aminoC₁-C₄alkyl, hydroxyC₁-C₄alkyl, carbonyl, cycloC₃-C₆alkyl or aminocarbonyl;

L₂ is phenylmethyl or phenylmethylaminocarbonyl, optionally substituted with chloro, fluoro, bromo, or methyl; and

optionally substituted at any of the 3, 5, 6, 7, or 8 positions independently with X, wherein X is hydroxy, amino, C₁-C₄alkylamino, di(C₁-C₄alkylamino), C₁-C₄alkyl, ester, carbamate, carbonate, or ether.

In an embodiment, the compound of this invention is represented by Formula (I) or a pharmaceutically acceptable salt thereof, wherein

R₁ is 2-benzimidazole;

R₂ is phenyl, optionally substituted with one to five substituents, each substituent independently being chloro, fluoro, bromo, C₁-C₄alkyl, trifluoromethyl, hydroxy, or carboxy;

L₁ is C₁-C₄alkyl, C₁-C₄alkenyl, C₁-C₄alkynyl, C₁-C₄alkoxy, aminoC₁-C₄alkyl, hydroxyC₁-C₄alkyl, carbonyl, cycloC₃-C₆alkyl or aminocarbonyl;

L₂ is phenylmethyl or phenylmethyaminocarbonyl, optionally
5 substituted with chloro, fluoro, bromo, or methyl; and
optionally substituted at any of the 3, 5, 6, 7, or 8 positions
independently with X, wherein X is hydroxy, amino, C₁-C₄alkylamino, di(C₁-
C₄)alkylamino, C₁-C₄alkyl, ester, carbamate, carbonate, or ether.

In another embodiment, the compound of this invention is represented
10 by Formula (I) or a pharmaceutically acceptable salt thereof, wherein

R₁ is 2-imidazopyridine;

R₂ is phenyl, optionally substituted with one to five substituents, each
substituent independently being chloro, fluoro, bromo, C₁-C₄alkyl, trifluoromethyl,
hydroxy, or carboxy;

L₁ is C₁-C₄alkyl, C₁-C₄alkenyl, C₁-C₄alkynyl, C₁-C₄alkoxy,
15 aminoC₁-C₄alkyl, hydroxyC₁-C₄alkyl, carbonyl, cycloC₃-C₆alkyl or
aminocarbonyl;

L₂ is phenylmethyl or phenylmethyaminocarbonyl, optionally
substituted with chloro, fluoro, bromo, or methyl; and

20 optionally substituted at any of the 3, 5, 6, 7, or 8 positions
independently with X, wherein X is hydroxy, amino, C₁-C₄alkylamino, di(C₁-
C₄)alkylamino, C₁-C₄alkyl, ester, carbamate, carbonate, or ether.

As used herein, "alkyl" as well as other groups having the prefix "alk"
such as, for example, alkoxy, alkanoyl, alkenyl, alkynyl and the like, means carbon
25 chains which may be linear or branched or combinations thereof. Examples of alkyl
groups include methyl, ethyl, propyl, isopropyl, butyl, sec- and tert-butyl, pentyl,
hexyl, heptyl and the like. "Alkenyl", "alkynyl" and other like terms include carbon
chains containing at least one unsaturated C-C bond.

The term "cycloalkyl" means carbocycles containing no heteroatoms,
30 and includes mono-, bi- and tricyclic saturated carbocycles, as well as fused ring
systems. Such fused ring systems can include one ring that is partially or fully
unsaturated such as a benzene ring to form fused ring systems such as benzofused
carbocycles. Cycloalkyl includes such fused ring systems as spirofused ring systems.
Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,

decahydronaphthalene, adamantane, indanyl, indenyl, fluorenyl, 1,2,3,4-tetrahydronaphthalene and the like. Similarly, "cycloalkenyl" means carbocycles containing no heteroatoms and at least one non-aromatic C-C double bond, and include mono-, bi- and tricyclic partially saturated carbocycles, as well as benzofused
5 cycloalkenes. Examples of cycloalkenyl include cyclohexenyl, indenyl, and the like.

Unless otherwise stated, the terms "carbonyl" and "aminocarbonyl" include short C₁-C₂ termini. The terms include, for example, -CH₂CONH-, -CH₂CO-, -C₂H₄CONHCH₂-, and -CH₂COC₂H₄-.

Unless otherwise stated, the term "carbamate" is used to include
10 -OCOOC₁-C₄alkyl, -NHCOOC₁-C₄alkyl, and -OCONHC₁-C₄alkyl.

The term "halogen" includes fluorine, chlorine, bromine and iodine atoms.

The term "SEM" is used to describe -CH₂-O-CH₂CH₂-Si(CH₃)₃.

The term "C₀" means that the carbon is not present. Thus, "C₀-C₅"
15 means that there are from none to five carbons present – that is, five, four, three, two, one, or no carbons present.

The term "optionally substituted" is intended to include both substituted and unsubstituted. Thus, for example, optionally substituted aryl could represent a pentafluorophenyl or a phenyl ring.

20 Compounds described herein contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers. The present invention includes all such possible diastereomers as well as their racemic mixtures, their substantially pure resolved enantiomers, all possible geometric isomers, and pharmaceutically acceptable salts thereof. The above Formula I is shown without a
25 definitive stereochemistry at certain positions. The present invention includes all stereoisomers of Formula I and pharmaceutically acceptable salts thereof. Further, mixtures of stereoisomers as well as isolated specific stereoisomers are also included. During the course of the synthetic procedures used to prepare such compounds, or in using racemization or epimerization procedures known to those skilled in the art, the
30 products of such procedures can be a mixture of stereoisomers.

The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids. When the compound of the present invention is acidic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and
35 organic bases. Salts derived from such inorganic bases include aluminum,

ammonium, calcium, copper (ic and ous), ferric, ferrous, lithium, magnesium, manganese (ic and ous), potassium, sodium, zinc and the like salts. Particularly preferred are the ammonium, calcium, magnesium, potassium and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of
5 primary, secondary, and tertiary amines, as well as cyclic amines and substituted amines such as naturally occurring and synthesized substituted amines. Other pharmaceutically acceptable organic non-toxic bases from which salts can be formed include ion exchange resins such as, for example, arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-
10 dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like.

15 When the compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic,
20 malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like. Particularly preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, and tartaric acids.

The pharmaceutical compositions of the present invention comprise a compound represented by Formula I (or pharmaceutically acceptable salts thereof) as
25 an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants. The compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the
30 active ingredient is being administered. The pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.

In practice, the compounds represented by Formula I, or pharmaceutically acceptable salts thereof, of this invention can be combined as the
35 active ingredient in intimate admixture with a pharmaceutical carrier according to

conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous). Thus, the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration
5 such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient. Further, the compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion or as a water-in-oil liquid emulsion. In addition to the common dosage forms set out above, the compound represented by Formula I, or
10 pharmaceutically acceptable salts thereof, may also be administered by controlled release means and/or delivery devices. The compositions may be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and
15 intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.

Thus, the pharmaceutical compositions of this invention may include a pharmaceutically acceptable carrier and a compound or a pharmaceutically acceptable
20 salt of Formula I. The compounds of Formula I, or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds.

The pharmaceutical carrier employed can be, for example, a solid, liquid, or gas. Examples of solid carriers include lactose, terra alba, sucrose, talc,
25 gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Examples of liquid carriers are sugar syrup, peanut oil, olive oil, and water. Examples of gaseous carriers include carbon dioxide and nitrogen.

In preparing the compositions for oral dosage form, any convenient pharmaceutical media may be employed. For example, water, glycols, oils, alcohols,
30 flavoring agents, preservatives, coloring agents and the like may be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to form oral solid preparations such as powders, capsules and tablets. Because of their ease of administration, tablets
35 and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers

are employed. Optionally, tablets may be coated by standard aqueous or nonaqueous techniques

A tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants. Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. Each tablet preferably contains from about 1mg to about 500mg of the active ingredient and each cachet or capsule preferably containing from about 1 to about 500mg of the active ingredient.

Pharmaceutical compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water. A suitable surfactant can be included such as, for example, hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.

Pharmaceutical compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions. Furthermore, the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions. In all cases, the final injectable form must be sterile and must be effectively fluid for easy syringability. The pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.

Pharmaceutical compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder, or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound represented by Formula I of this invention, or pharmaceutically acceptable salts thereof, via conventional processing methods. As an example, a cream or ointment is prepared by mixing hydrophilic material and water, together with about 5

wt% to about 10 wt% of the compound, to produce a cream or ointment having a desired consistency.

Pharmaceutical compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier(s) followed by chilling and shaping in moulds.

In addition to the aforementioned carrier ingredients, the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like. Furthermore, other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient. Compositions containing a compound described by Formula I, or pharmaceutically acceptable salts thereof, may also be prepared in powder or liquid concentrate form.

Experimental Protocols

Assessing the Activity of Selected Compounds to Inhibit NR1A/2B NMDA Receptor Activation (FLIPR Assay)

The activity of selected compounds to inhibit NR1A/2B NMDA receptor activation measured as NR1A/2B receptor-mediated Ca^{2+} influx is assessed by the following procedure:

NR1A/2B receptor transfected L(tk) cells are plated in 96-well format at 3×10^6 cells per plate and grown for one - two days in normal growth media (Dulbeccos MEM with Na pyruvate, 4500 mg glucose, pen/strep, glutamine, 10% FCS and 0.5mg/ml geneticin). NR1A/2B-expression in these cells is induced by the addition of 4nM dexamethasone in the presence of 500 μM ketamine for 16 - 24 hours. After receptor induction cells are washed using a Labsystem Cellwasher two times with assay buffer (Hanks balanced salt solution (HBSS- Mg^{++} free) containing 20mM HEPES, 0.1% BSA, 2mM CaCl_2 and 250 μM probenecid). The cells of each 96 well cell plate are loaded with the Ca^{++} sensitive dye Fluo-3 (Molecular Probes, Inc.) at 4 μM in assay buffer containing 0.5% FBS, and 0.04% pluronic F-127 (Molecular

Probes, Inc.) for 1h at 37 °C avoiding light. The cells are then washed with the Cellwasher four times with assay buffer leaving them in 100µl buffer. Test compounds in solution are pipetted by FLIPR (Fluorometric Imaging Plate Reader) into each test well for a 2min pretreatment. During this time the fluorescence intensity is recorded (excitation at 488nm and emission at 530nm). The glutamate/glycine 50µL agonist solution (final concentration 1µM/1µM) is then added by FLIPR into each well already containing 150µL of buffer (containing the test compound or vehicle) and the fluorescence is continuously monitored for 10min. The endpoint fluorescence values are used to determine an IC₅₀ value comparing the agonist-stimulated signal for the vehicle alone sample and that for the cells incubated with each concentration of test compound.

15 **Determining the Apparent Dissociation Constant (K_i) of Compounds
for Human NR1A/NR2B Receptors (Binding Assay):**

The radioligand binding assay is performed at room temperature in 96-well microtiter plates with a final assay volume of 1.0mL in 20mM Hepes buffer (pH 7.4) containing 150mM NaCl. Solutions of test compounds were prepared in DMSO and serially diluted with DMSO to yield 20μL of each of 10 solutions differing by 3-fold in concentration. Non-specific binding (NSB) using hot AMD-1 (10μM final concentration) and total binding (TB) by using DMSO (2% final concentration). A solution of NR1A/NR2B receptors (40pM final concentration) and tritiated AMD-2 (1nM final concentration) were added to the test compounds. After 3h of incubation at room temperature, samples are filtered through Packard GF/B filters (presoaked in 0.05% PEI, polyethylenimine Sigma P-3143) and washed 10 times with 1mL of cold 20mM Hepes buffer per wash. After vacuum drying of the filter plates, 40μL of Packard Microscint-20 was added and bound radioactivity determined in a Packard TopCount. The apparent dissociation constant (K_i), the maximum percentage inhibition ($\%I_{max}$), the minimum percentage inhibition ($\%I_{min}$) and the hill slope (nH) were determined by a non-linear least squares fitting the bound CPM data to Equation #1 below.


Equation#1:

$$\text{CPM Bound} = \frac{(\text{SB}) (\%I_{\text{max}} - \%I_{\text{min}})}{(\%I_{\text{max}})} + \text{NSB} + (\text{SB}) (1 - (1 + ([\text{Drug}] / (\text{Ki} [\text{L-844,345}]/K_D))^{\text{NH}}))$$


5

where, K_D is the apparent dissociation constant for the radioligand for the receptor as determined by hot saturation and SB is the specifically bound CPM determined from the difference of TB and NSB.

10 AMD-1




AMD-2



15 Compounds AMD-1 and AMD-2 can be synthesized in accordance with the following general reaction schemes.


SCHEME 1



In accordance with scheme 1, hydrogen chloride is bubbled through a solution of the appropriately substituted benzonitrile 1 in methanol at room temperature. The volatiles are removed under reduced pressure and the resulting residue is triturated with ether and filtered to yield the desired imidate 2. Imidate 2 is dissolved in methanol at ambient temperature, treated with amine 3 at ambient temperature and stirred under argon. The volatiles are removed under reduced pressure and the residue purified by preparative HPLC or trituration with ether to afford amidine Ia.

10


SCHEME 2



In accordance with scheme 2, at room temperature under argon, amine 3a is dissolved in ether and was treated with 1-M hydrogen chloride in ether (1 equiv.) in a single portion. The resulting precipitate is stirred vigorously for 10 minutes. The volatiles are removed under reduced pressure. The residue is suspended in toluene, cooled to 0°C under argon, treated with 2.0-M trimethylaluminum (1.05 equiv.) in a dropwise manner, and stirred for 45 minutes at room temperature to afford intermediate 6 (not isolated). Compound 6 is added to a solution of nitrile 1 in toluene. The reaction is heated to 80°C without stirring in a sealed tube for 18h, cooled to ambient temperature, poured onto a silica gel column and eluted with methanol/dichloromethane to give the amidine 4.

25

Preparation of [¹²⁵I]AMD-1



Tritiated AMD-1 was prepared by the following procedure: A mixture of AMD-1, hydrochloride salt, (5mg, 0.012mmol) in dioxane (0.2mL) containing triethylamine (4μL) was treated with hexamethylditin (5μL), a catalytic amount of palladium catalyst and heated at 100°C for 45 minutes. The reaction was cooled to room temperature, filtered through a glass wool plug, rinsed with methanol and concentrated *in vacuo* to give 10.7mg of a brown oil. The oil was dissolved in methylene chloride and passed through a small silica column eluting with methylene chloride followed by 5% methanol/methylene chloride. Fractions containing the trimethylstannane (R_f 0.26 in 10% methanol/methylene chloride) were pooled and concentrated *in vacuo* to give 4.5mg of the trimethylstannane as a clear colorless oil. This material was further purified by HPLC (C18 Econosil, 10x250mm, 20 minute linear gradient, 30% MeCN:70% H₂O (0.1% TFA) to 90% MeCN, 3mL/min, 254nm, retention time 15 minutes) to give 3mg of the trimethylstannane.

A Na¹²⁵I shipping vial (10mCi, Amersham) was charged with a stir bar, an iodobead, 50μL of methanol and stirred five minutes at room temperature. A solution of the trimethylstannane (0.1mg) in 50μL of methanol containing 5μL of trifluoroacetic acid was added and the reaction was stirred for five minutes. The reaction was quenched with 50μL of ammonium hydroxide and purified by HPLC (C18 Vydac protein and peptide column, 4.6 x 250 mm, 20 minute linear gradient,

30% MeCN:70% H₂O (0.1% TFA) to 90% MeCN, 1mL/min, retention time 11 minutes). Fractions containing the radioactive product were pooled and concentrated *in vacuo* to give 989µCi of [¹²⁵I]AMD-1 with a specific activity of 898Ci/mmol as measured by UV absorbance at 272nm.

5

Synthesis of Tritiated AMD-2

Tritiated AMD-2 was prepared by the following procedure: The phenol of AMD-2 (2mg, 0.008mmol) dissolved in dimethylformamide (0.6mL) and potassium carbonate (1.2mg) for 1hr. High specific activity tritiated methyl iodide (50mCi, 0.0006mmol, in toluene 1mL, American Radiolabeled Chemicals) was added at room temperature and stirred for 2 hours. The reaction mixture was filtered using a Whatman PTFE 0.45µm syringeless filter device to remove any insoluble potassium carbonate, washed with Abs. ethanol (2mL, Pharmco), and the combined filtrates were concentrated to dryness at room temperature using a rotary evaporator; this also removed any unreacted tritiated methyl iodide. The residue was purified by HPLC chromatography on a Phenomenx Luna C8 semi-prep column (Luna 5 micro C8(2), 250x10.0 mm) using a gradient system of 20/80 acetonitrile/water with 0.1% trifluoroacetic acid to 100% acetonitrile with 0.1% trifluoroacetic acid in 20min. Total activity of the product was 8mCi. Further purification was effected by absorption onto a Waters C-18 Sep-pak column (Waters Sep-Pak PLUS C18) and elution with water followed by absolute ethanol. The product was diluted with absolute ethanol (10mL) before submission for final analysis.

The compounds of this invention exhibit less than 50µM in the FLIBR and binding assays. Thus, the compounds and pharmaceutical compositions of this invention have been found to exhibit biological activity as NMDA NR2B antagonists. Accordingly, another aspect of the invention is the treatment of pain, migraine, depression, anxiety, schizophrenia, Parkinson's disease, or stroke – maladies that are amenable to amelioration through inhibition of NMDA NR2B receptors – by the administration of an effective amount of the compounds of this invention.


The following examples are provided to more fully illustrate the present invention, and are not to be construed as limiting the scope of the claims in any manner.

35

EXAMPLES


Compounds of this invention can be prepared by Scheme 1 below.

Scheme 1




Compounds of this invention can be prepared by Scheme 2 below.




Scheme 2

















In Schemes 1 and 2, in place of the 1-SEM-benzimidole-2-carboxaldehyde




any of the following aldehydes, ketones, or bromides can be used to prepare the compounds of this invention:




$n = 0, 1, 2, 3$



EXAMPLE 1**2-(1H-Benzimidazol-2-ylmethyl)-5-(4-chloro-benzyl)-2-aza-bicyclo[2.2.2]octane**

5 Example 1 was prepared by the following procedure.

Step 1:**1-(2-Trimethylsilylethoxymethyl)-1H-benzimidazole:**


10 A mixture of KH, from 7g of 30% oil dispersion, and 5g of benzimidazole in 100mL of THF was stirred under nitrogen at room temperature for 18h. To the stirred suspension was added 7g of 2-trimethylsilylethoxymethyl chloride and the mixture kept at room temperature for 24h, cooled in an ice bath, cautiously quenched with 50mL of water, and extracted into ether. The combined ether extracts were dried over magnesium sulfate and concentrated. Low pressure chromatography
15 over silica gel eluting with a gradient of 3:1 ethyl acetate:hexane to 100% ethyl acetate gave 9.5g of 1-SEM-benzimidazole as a colorless oil.

Step 2:

20 **1-(2-Trimethylsilylethoxymethyl)-1H-benzimidazole-2-carbaldehyde:**

To a solution of 40mmole of lithium diisopropylamide in 100mL of THF cooled to -78°C was added 5g of 1-SEM-benzimidazole in 50mL of THF. After 1.5h at or below -70°C, the red solution was quenched by rapid addition of 6mL of methyl formate. After warming to room temperature over 30min, 50mL of water and
5 200mL of ethyl acetate were added. The organic layer was separated and dried over magnesium sulfate then concentrated under reduced pressure to 5.3g of a thick oil that solidified in the freezer.


Step 3:



10


5-(4-Chloro-benzylidene)-2-aza-bicyclo[2.2.2]octane-2-carboxylic acid ethyl ester:

To a stirred solution of 2g of 5-Oxo-2-aza-bicyclo[2.2.2]octane-2-carboxylic acid ethyl ester (G. Krow, R. Rodebaugh, M. Grippi and R. Carmosin,
15 *Synthetic Communications*, 2:211-214(1972)) and 3.5g of diethyl 4-chlorobenzylphosphonate in 10mL of 1,3-dimethyl-2-imidazolidinone dried over 4Å mol sieves was added 0.50g of 60% sodium hydride oil dispersion. The mixture was allowed to stir overnight, diluted with 200mL of water and extracted with 3X100mL of ether. Combined extracts were dried over magnesium sulfate and concentrated
20 under reduced pressure. Low pressure chromatography over silica gel eluting with a gradient of 5:95 ethyl acetate:hexane to 1:5 ethyl acetate:hexane gave 2g of 5-(4-chloro-benzylidene)-2-aza-bicyclo[2.2.2]octane-2-carboxylic acid ethyl ester as a colorless oil.

Step 4:**5-(4-Chloro-benzyl)-2-aza-bicyclo[2.2.2]octane-2-carboxylic acid ethyl ester:**

- A solution of 2g of 5-(4-chloro-benzylidene)-2-aza-bicyclo[2.2.2]octane-2-carboxylic acid ethyl ester and 0.5g of 5% platinum on carbon in 100mL of ethanol was allowed to stir overnight under 1atm of hydrogen. The catalyst was filtered off and the solution concentrated to give 2g of a racemic mixture of exo:endo isomers of 5-(4-chloro-benzyl)-2-aza-bicyclo[2.2.2]octane-2-carboxylic acid ethyl ester as an oil.


10

Step 5:**5-(4-Chloro-benzyl)-2-aza-bicyclo[2.2.2]octane:**

- A mixture of 2g of 3-(4-chloro-benzyl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid ethyl ester, 20mL of 48% HBr and 5mL of acetic acid was heated to reflux for 2h. After cooling in an ice bath the solution was basified to pH 10 by addition of NaOH pellets, extracted with 3X100mL of chloroform and the combined extracts dried over magnesium sulfate. Removal of solvents under reduced pressure gave 1.5g of racemic exo and endo 5-(4-chloro-benzyl)-2-aza-bicyclo[2.2.2]octane as a thick oil.

20

Step 6:


**2-[3-(4-Chloro-benzyl)-8-aza-bicyclo[3.2.1]oct-8-ylmethyl]-1H-benzimidazole:**

A mixture of 0.5g of racemic *exo* and *endo* 5-(4-chloro-benzyl)-2-aza-bicyclo[2.2.2]octane, 0.5g of 1-(2-trimethylsilylethoxymethyl)-1H-benzimidazole-2-carbaldehyde, 5mL of 1,2-dichloroethane and 0.5g of sodium triacetoxyborohydride was stirred at room temperature for 48h. The reaction mixture was diluted with 50mL chloroform and 10mL saturated aqueous Na₂CO₃ and the layers separated. The aqueous layer was extracted with 2X25mL of chloroform and the combined organic layers dried over magnesium sulfate and concentrated under reduced pressure. The crude SEM ether was heated to reflux in 50mL of ethanol containing 5mL of 3N HCl for 2h, cooled, concentrated and partitioned between 10mL of saturated aqueous sodium carbonate and 3X25mL of chloroform. The chloroform extracts were dried over magnesium sulfate and concentrated. Purification by chromatography eluting with 90:10 CHCl₃:MeOH gave 0.8g of 2-[3-(4-chloro-benzyl)-8-aza-bicyclo[3.2.1]oct-8-ylmethyl]-1H-benzimidazole as a mixture of *exo* and *endo* isomers. Chromatography on a Chiralpak™ OD column eluting with a 90:10 mixture of hexane with 0.10% diethylamine and isopropanol gave 0.2g of 2-(1H-benzimidazol-2-ylmethyl)-5-*exo*-(4-chloro-benzyl)-2-aza-bicyclo[2.2.2]octane, enantiomer A: RT = 8.75min; MS (m+1) = 366.9; ¹H NMR (400MHz, CDCl₃) 7.6 (br, 2H), 7.22 (d, 2H), 7.08 (d, 2H), 4.05 (s, 2H), 3.05 (d, 1H), 2.8 (d, 1H), 2.7 (m, 2H), 2 (m, 2H), 1.8-1.5 (complex, 6H), 1.25 (m, 1H).

Later fractions gave 0.2g of 2-(1H-benzimidazol-2-ylmethyl)-5-*exo*-(4-chloro-benzyl)-2-aza-bicyclo[2.2.2]octane, enantiomer B: RT = 10.7min; MS (m+1) = 366.9; ¹H NMR (400MHz, CDCl₃) 7.6 (br, 2H), 7.22 (d, 2H), 7.08 (d, 2H), 4.05 (s, 2H), 3.05 (d, 1H), 2.8 (d, 1H), 2.7 (m, 2H), 2 (m, 2H), 1.8-1.5 (complex, 6H), 1.25 (m, 1H).

Even later fractions gave 0.4g of racemic 2-(1H-benzimidazol-2-ylmethyl)-5- *endo* -(4-chloro-benzyl)-2-aza-bicyclo[2.2.2]octane: RT = 12.52min; MS (m+1) = 366.9; ¹H NMR (400MHz, CDCl₃) 7.6 (br, 2H), 7.22 (d, 2H), 7.08 (d, 2H), 4.05 (s, 2H), 2.85 (dd, 2H), 2.6 (m, 3H), 2.2 (m, 2H), 2.1 (m, 1H), 1.85 (m, 1H), 1.7 (m, 1H), 1.55 (m, 3H).

EXAMPLE 2



10 2-(1H-Benzimidazol-2-ylmethyl)-5-benzyl-2-aza-bicyclo[2.2.2]octane


Example 2 was prepared following the procedures described for Example 1, but substituting diethyl benzylphosphonate for diethyl 4-chlorophosphonate. Chromatography on a Chiralpak™ AD column eluting with a 90:10 mixture of hexane with 0.10% diethylamine and isopropanol, yielded 2-(1H-benzimidazol-2-ylmethyl)-5-*exo*-(benzyl)-2-aza-bicyclo[2.2.2]octane, enantiomer A: RT = 6.97min; MS (m+1) = 332.2; ¹H NMR (400MHz, CDCl₃) 1.50-1.60(m, 2H), 1.62-1.80 (m, 4H), 1.92-2.10 (m, 2H), 2.60(s, 1H), 2.70-2.81 (m, 3H), 3.05 (d, J=17 Hz 1H), 4.05 (s, 2H), 7.20-7.25 (m, 2H), 7.26-7.35 (m, 5H), 7.45-7.50 (br s, 1H), 7.75 (br s, 1H), 9.70 (br s, 1H).

Later fractions gave 2-(1H-benzimidazol-2-ylmethyl)-5-*exo*-(benzyl)-2-aza-bicyclo[2.2.2]octane, enantiomer B: RT = 8.5min; MS (m+1) = 332.2; ¹H NMR (400MHz, CDCl₃) 1.50-1.60(m, 2H), 1.62-1.80 (m, 4H), 1.92-2.10 (m, 2H), 2.60(s, 1H), 2.70-2.81 (m, 3H), 3.05 (d, J=17 Hz 1H), 4.05 (s, 2H), 7.20-7.25 (m, 2H), 7.26-7.35 (m, 5H), 7.45-7.50 (br s, 1H), 7.75 (br s, 1H), 9.70 (br s, 1H).

Still later fractions gave racemic 2-(1H-benzimidazol-2-ylmethyl)-5-*endo*-(benzyl)-2-aza-bicyclo[2.2.2]octane: RT = 10.2 and 12.15min; MS (m+1) = 332.2; ¹H NMR (400MHz, CDCl₃) 1.95-1.22 (m, 1H), 1.45-1.65 (m, 3H), 1.80-1.90

(m, 1H), 1.92-2.10 (m, 1H), 2.20-2.25 (m, 2H), 2.60-2.80 (m, 4H), 2.85 (d, J=18 Hz 1H), 4.00 (s, 2H), 7.15-7.25 (m, 5H), 7.30-7.35 (m, 2H), 7.42 (br s, 1H), 7.70 (br s, 1H), 9.95 (br s, 1H).

5


EXAMPLE 3

5-(4-Chloro-benzyl)-2-(3H-imidazo[4,5-b]pyridin-2-ylmethyl)-2-aza-bicyclo[2.2.2]octane

10 Example 3 was prepared in a similar manner to Example 1, Steps 1-6, but substituting 3H-imidazo[4,5-b]pyridine for benzimidazole in Step 2. Chromatography on a Chiralpak™ AD column eluting with a 90:10 mixture of hexane with 0.10% diethylamine and isopropanol gave racemic 5-*exo*-(4-chloro-benzyl)-2-(3H-imidazo[4,5-b]pyridin-2-ylmethyl)-2-aza-bicyclo[2.2.2]octane: RT = 6.03min; MS (m+1) = 367.2; ¹H NMR (400MHz, CDCl₃) 8.4 (s, 1H), 8.0 (s, 1H), 7.35-7.2 (m, 15 3H), 7.1 (d, 2H), 4.05 (s, 2H), 3.1 (d, 1H), 2.8-2.62 (m, 4H), 2.60 (s, 1H), 2.1-1.90 (m, 2H), 1.8-1.72 (m, 2H), 1.70-1.61 (m, 1H).

Later fractions gave 5-*endo*-(4-chloro-benzyl)-2-(3H-imidazo[4,5-b]pyridin-2-ylmethyl)-2-aza-bicyclo[2.2.2]octane, enantiomer A: RT = 7.5min; MS (m+1) = 367.2; ¹H NMR (400MHz, CDCl₃) 8.4 (s, 1H), 8.0 (s, 1H), 7.35-7.2 (m, 20 3H), 7.1 (d, 2H), 4.05 (s, 2H), 2.9-2.8 (dd, 2H), 2.62 (m, 3H), 2.2 (m, 2H), 2.0 (m, 1H), 1.5 (m, 3H) 1.3 (m, 1H), 1.08 (m, 1H).

Still later fractions gave 5-*exo*-(4-chloro-benzyl)-2-(3H-imidazo[4,5-b]pyridin-2-ylmethyl)-2-aza-bicyclo[2.2.2]octane, enantiomer B: RT = 8.1min; MS (m+1) = 367.2; ¹H NMR (400MHz, CDCl₃) 8.4 (s, 1H), 8.0 (s, 1H), 7.35-7.2 (m, 25 3H), 7.1 (d, 2H), 4.05 (s, 2H), 2.9-2.8 (dd, 2H), 2.62 (m, 3H), 2.2 (m, 2H), 2.0 (m, 1H), 1.5 (m, 3H) 1.3 (m, 1H), 1.08 (m, 1H).

EXAMPLE 4**5 2-(3-Benzyl-8-aza-bicyclo[3.2.1]oct-8-ylmethyl)-3H-imidazo[4,5-b]pyridine**

Example 4 was prepared in a similar manner to Example 3, but substituting racemic *exo* and *endo* 5-(benzyl)-2-aza-bicyclo[2.2.2]octane for racemic *exo* and *endo* 5-(4-chloro-benzyl)-2-aza-bicyclo[2.2.2]octane. Chromatography on a Chiralpak™ AD column eluting with a 95:5 mixture of hexane with 0.10%


- 10 diethylamine and isopropanol gave racemic 5-*exo*-(benzyl)-2-(3H-imidazo[4,5-b]pyridin-2-ylmethyl)-2-aza-bicyclo[2.2.2]octane: RT = 6.03min; MS (m+1) = 333.2; ¹H NMR (400MHz, CDCl₃) 4.10 (s, 2H), 3.15 (d, 2H), 2.8 (d, 2H).

- Later fractions gave 5-*endo*-(benzyl)-2-(3H-imidazo[4,5-b]pyridin-2-ylmethyl)-2-aza-bicyclo[2.2.2]octane, enantiomer A: RT = 7.53min; MS (m+1) = 333.2; ¹H NMR (400MHz, CDCl₃) 4.05 (s, 2H), 2.90 (d, 2H), 2.8 (d, 2H).

15 Still later fractions gave 5-*exo*-(benzyl)-2-(3H-imidazo[4,5-b]pyridin-2-ylmethyl)-2-aza-bicyclo[2.2.2]octane, enantiomer B: RT = 8.09min; MS (m+1) = 333.2; ¹H NMR (400MHz, CDCl₃) 4.05 (s, 2H), 2.90 (d, 2H), 2.8 (d, 2H).

WHAT IS CLAIMED IS:

1. A compound having the formula:



5 or a pharmaceutically acceptable salt thereof, wherein

R_1 is 2-benzimidazole, 4-imidazole, 2-imidazopyridine, 2-indole, 2-quinazoline, or 4-phenol;

R_2 is phenyl, optionally substituted with one to five substituents, each substituent independently being chloro, fluoro, bromo, C_1 - C_4 alkyl, trifluoromethyl, hydroxy, or carboxy;

10

L_1 is C_1 - C_4 alkyl, C_1 - C_4 alkenyl, C_1 - C_4 alkynyl, C_1 - C_4 alkoxy, amino C_1 - C_4 alkyl, hydroxy C_1 - C_4 alkyl, carbonyl, cyclo C_3 - C_6 alkyl or aminocarbonyl;

L_2 is phenylmethyl or phenylmethyaminocarbonyl, optionally substituted with chloro, fluoro, bromo, or methyl; and

15

optionally substituted at any of the 3, 4, 5, 6, 7, or 8 positions independently with X, wherein X is hydroxy, amino, C_1 - C_4 alkylamino, di(C_1 - C_4)alkylamino, C_1 - C_4 alkyl, ester, carbamate, carbonate, or ether.

20 2. The compound according to claim 1, wherein R_1 is 2-benzimidazole.

3. The compound according to claim 1, wherein R_1 is 2-imidazopyridine.




25

4. The compound according to claim 1, wherein said compound is 2-(1H-Benzimidazol-2-ylmethyl)-5-(4-chloro-benzyl)-2-aza-bicyclo[2.2.2]octane;


2-(1H-Benzimidazol-2-ylmethyl)-5-benzyl-2-aza-bicyclo[2.2.2]octane;
 5-(4-Chloro-benzyl)-2-(3H-imidazo[4,5-b]pyridin-2-ylmethyl)-2-aza-
 bicyclo[2.2.2]octane; or
 2-(3-Benzyl-8-aza-bicyclo[3.2.1]oct-8-ylmethyl)-3H-imidazo[4,5-b]pyridine.

5

5. The compound according to claim 1, wherein said compound is



10 or



6. A pharmaceutical composition comprising an inert carrier and an effective amount of a compound according to claim 1.

5

7. The pharmaceutical composition according to claim 6 useful for the treatment of pain.

8. The pharmaceutical composition according to claim 6 useful for the treatment of migraine, depression, anxiety, schizophrenia, Parkinson's disease, or stroke.

10

9. A method of treating pain comprising a step of administering to one in need of such treatment an effective amount of a compound according to claim 1.

15

10. A method of treating migraine, depression, anxiety, schizophrenia, Parkinson's disease, or stroke comprising a step of administering to one in need of such treatment an effective amount of a compound according to claim 1.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/29577

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :A61K 31/439; C07D 221/22, 401/08

US CL :514/299, 303; 546/112, 118

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/299, 303; 546/112, 118

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,889,019 A (MITCH) 30 March 1999 (30/03/99), see entire document, especially columns 1-3.	1-10
A	HERDEIS et al. Electron-rich 2-Pyridones, III: Stereochemistry and Reactivity of Phenylsulfonyl-substituted 2-Azabicyclo[2.2.2]octan-6-ones. Arch. Pharm. November 1990, Volume 323, Number 11, pages 937-942, especially page 937.	1-10

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A document defining the general state of the art which is not considered to be of particular relevance	X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E earlier document published on or after the international filing date	T	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	A	document member of the same patent family
*O document referring to an oral disclosure, use, exhibition or other means		
*P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

13 DECEMBER 2000

Date of mailing of the international search report

26 FEB 2001

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 308-3230

Authorized officer
LAURA STOCKTON

Telephone No. (703) 308-1235